Abstracts from the Myeloma Institute Accepted for Presentation at 2011 Annual Meeting of the American Hematology Society

Abstracts accepted for oral presentation

Second Malignancies in Total Therapy 3 Trials for Newly Diagnosed Multiple Myeloma: Influence of Lenalidomide Versus Thalidomide in Maintenance Phases
Saad Usmani, MD, first author
This abstract was selected by the abstract reviewers and the ASH Program Committee as one of the top submissions for presentation

Secreted Frizzled-Related Protein-3 (sFRP3) Is Produced by Myeloma Cells and Augments Wnt3a-Induced Differentiation of Mesenchymal Stem Cells and OPG Production in Osteoblasts.
Ya-wei Qiang, MD, PhD, first author

Prediction of Cytogenetic Abnormalities in Multiple Myeloma Based on Gene Expression Profiles
Yiming Zhou, PhD, first author

Low Expression of Nuclear Glucocorticoid Receptor Gene NR3C1 in Newly Diagnosed Myeloma Correlates with Inferior Prognosis and Is Rescued by Thalidomide
Christoph Heuck, MD, first author

Inducible Heme Oxygenase 1 (HMOX1) Promotes Osteoblastogenesis, and Inhibits Osteoclastogenesis and Myeloma-Induced Bone Disease.
Xin Li, PhD, first author

NAMPT/PBEF Enzymatic Activity is Indispensable for Myeloma Cell Growth and Osteoclast Activity
Satisha Upparahalli Venkateshaiah, PhD, first author

Cell Surface CXCR4 and BTK Expression are Associated in Myeloma Cells and Osteoclast Precursors and Mediate Myeloma Cell Homing and Clonogenicity, and Osteoclastogenesis
Rakesh Bam, first author 

---

Abstracts accepted for poster presentation

 

Implications of Serial Magnetic Resonance Imaging and Positron Emission Tomography Scanning for Survival of Untreated Myeloma Patients Treated with Total Therapy 3
Saad Usmani, MD, first author

Pomalidomide (Pom) in Relapsed and Refractory Multiple Myeloma (RRMM) - theUARK Compassionate Use Protocol
Saad Usmani, MD, first author

Phase II Study of Carfilzomib (CFZ) Combined with Other Anti-Myeloma Agents in Relapsed-Refractory Multiple Myeloma (RRMM) - Updates on the UARK Compassionate Use Protocol
Saad Usmani, MD, first author

Total Therapy 6: Initial Results of Dose-Dense Strategy for Previously Treated Multiple Myeloma
Saad Usmani, MD, first author

Pharmacodynamic, Biodistribution and Toxicology Results for SNS01-T, a Nanoparticle That Targets eIF5A for the Treatment of Multiple Myeloma
Saad Usmani, MD, first author

Long-Term Safety in a Phase 1 Study of Siltuximab (CNTO 328), an Anti-Interleukin-6 Monoclonal Antibody in Patients with B-Cell Non-Hodgkin’s Lymphoma, Multiple Myeloma, or Castleman’s Disease
Frits van Rhee, MD, PhD and Saad Usmani, MD, co-authors

Thrombin-Induced PARI Signaling Pathway Modulates ß-Catenin in the Transformation of Symptomatic Myeloma Cells Into the Quiescent Phenotype
Erming Tian, PhD, first author

Bortezomib Induces Activation of b-Catenin/TCF Signaling Pathway in Multiple Myeloma
Ya-wei Qiang, MD, PhD, first author

Autologous Expanded Natural Killer Cells as a New Therapeutic Option for High-Risk Myeloma
Tarun K Garg, PhD, first author

Expression Profiling (GEP) Analysis of Plasma Cells (PC) Obtained From MRI-Defined Focal Lesions (FL) Under CT-Guided Fine-Needle Aspiration Provides Better Risk Stratification in Patients with Multiple Myeloma
Qing Zhang, PhD, first author

SWOG S0120 Observational Trial for MGUS and Asymptomatic Multiple Myeloma (AMM): Imaging Predictors of Progression for Patients Treated At UAMS
Christoph Heuck, MD, first author

Deregulated Cellular Iron Metabolism Factors Mediate Iron Overload in Myeloma Cells and Osteoclasts, and Promote Myeloma Growth and Bone Disease
Rakesh Bam, first author

Stearoyl CoA Desaturase 1(SCD1) is Upregulated in Rapidly Growing Myeloma Cells and is Required for Cell Proliferation
Sathisha Upparahalli Venkateshaiah, PhD

---

From the UAMS Department of Pathology:

Abstract accepted for oral presentation

Jumping Translocations 1q12 Contribute to Copy Number (CN) Alterations in Multiple Myeloma (MM):  Unexpected Focal Amplifications of Receptor Chromosomes (RC) 
Jeffrey Sawyer, PhD, first author

Abstract accepted for poster presentation

A Better Mobilization Regimen for Newly Diagnosed Multiple Myeloma Patients
Ahmed Abuabdou, MD, first author

---

Two abstracts were selected to receive a $500 ASH Abstract Achievement Award, which recognizes the accomplishment of being a trainee abstract presenter:

Cell Surface CXCR4 and BTK Expression are Associated in Myeloma Cells and Osteoclast Precursors and Mediate Myeloma Cell Homing and Clonogenicity, and Osteoclastogenesis
Rakesh Bam, first author

NAMPT/PBEF Enzymatic Activity is Indispensable for Myeloma Cell Growth and Osteoclast Activity
Satisha Upparahalli Venkateshaiah, PhD, first author